Johnson & Johnson

News

combination of directions for booted feet, two arrows

J&J says Rybrevant combo has survival edge over Tagrisso

Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.

News

FDA dents J&J's blockbuster hopes for Rybrevant

FDA has sent a complete response letter to J&J, denying approval of its subcutaneous version of lung cancer therapy Rybrevant.

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

News

J&J plots filings after psoriasis drug clears phase 3 test

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

News

J&J bids to add smouldering myeloma to Darzalex label

Johnson & Johnson has reported positive phase 3 data with Darzalex in smouldering multiple myeloma (SMM), just before filing applications for the drug in this indication in Europe and t

News

Pharmas ask appeals court to reconsider IRA lawsuits

The pharma industry's challenge to Medicare drug price negotiation powers continues to rumble on, with three drugmakers asking a US appeals court to revive their lawsuits.

J&J says Rybrevant combo has survival edge over Tagrisso

FDA dents J&J's blockbuster hopes for Rybrevant

ICER identifies new crop of 'unsupported' drug price rises

J&J plots filings after psoriasis drug clears phase 3 test

J&J bids to add smouldering myeloma to Darzalex label

Pharmas ask appeals court to reconsider IRA lawsuits

Protego's $130m for amyloidosis drug, and other financings

How to meet your physicians where they are online

Johnson & Johnson

Editor's Picks